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The American Society for Parenteral and Enteral
Nutrition (A.S.P.E.N.) is a professional society of
physicians, nurses, dietitians, pharmacists, allied
health professionals, and researchers dedicated to
assuring that every patient receives optimal nutri-
tion care. A.S.P.E.N.’s mission is to serve as the
preeminent, interdisciplinary nutrition society ded-
icated to patient-centered, clinical practice world-
wide through advocacy, education, and research in
the field of specialized nutrition support. These
Standards for Specialized Nutrition Support: Home
Care Patients are an update of the 1999 standards.
These standards present a range of performance of
competent care based on expert clinical opinion that
should be subscribed to by any home care provider
caring for patients receiving home enteral or paren-
teral nutrition. A separate reference, “Guidelines for
the Use of Parenteral and Enteral Nutrition in
Adults and Pediatric Patients,”1 provides evidence-
based practice guidelines that are coded to reflect
the strength of evidence supporting the guideline to
assist clinicians in their decision-making process in
the development of nutrition care plans (NCP) for
patients.
Use of the word shall within this document indi-
cates standards to be followed strictly to conform to
the standard; use of should indicates that among
several possibilities, one is particularly suitable,
without mentioning or excluding others, or that a
certain course of action is preferred but not neces-
sarily required. May is used to indicate a course of
action that is permissible within the limits of recom-
mended practice. A list of definitions is included in
the last chapter of this standard to assist the reader
in understanding terms used in this standard.
The standards are presented in the most generic
terms possible. The details of specific tests, thera-
pies, and protocols are left to the discretion of
individual home care providers. Each home care
provider shall strive to provide the best nutrition
support structure that is possible, given the
resources of the organization. The standards aim to
assure sound and efficient nutrition education and
care for those patients in need of home enteral or
PN.
These standards do not constitute medical or
other professional advice and should not be taken as
such. To the extent that the information published
herein may be used to assist in the care of patients,
this is the result of the sole professional judgment of
the attending healthcare professional whose judg-
ment is the primary component of quality medical
care. The information presented in these standards
is not a substitute for the exercise of such judgment
by the healthcare professional. These standards
have been developed, reviewed, and approved by
the A.S.P.E.N. Standards Committee and the
A.S.P.E.N. Board of Directors.
CHAPTER I: Organization
Standard 1. Nutrition Support Services
Interdisciplinary nutrition care planning shall be
achieved through collaboration of the referring phy-
sician, home care provider, and nutrition support
practitioner(s).
1.1. The role of each healthcare professional is
clearly defined and responsibilities are des-
ignated.2–5
1.2. The physician who has expertise in home
parenteral nutrition (PN) and enteral nutri-
tion (EN) support or a physician who works
with a multidisciplinary team primarily
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should be responsible for the patient’s nutri-
tion care. The physician should act in collab-
oration with a nurse,* dietitian,* pharma-
cist,* and other healthcare professionals as
needed. Each healthcare professional shall
demonstrate competency in nutrition sup-
port.2–5
1.3. Home PN and EN support shall be initiated,
modified, supervised, evaluated, and coordi-
nated by the referring physician, home care
provider, and nutrition support practitio-
ner(s).
*Use of the titles nurse, dietitian, and pharmacist
refers to registered nurse, registered dietitian, and
registered pharmacist.
Standard 2. Policies and Procedures
The referring physician, home care provider, and
nutrition support practitioner(s) managing care for
a patient receiving home PN and EN shall be guided
by policies, procedures, and other written processes.
2.1. Policies and procedures shall be appropriately
developed, reviewed, revised, and dated to
reflect optimal standards of care.
2.2. There shall be written policies and procedures
concerning the scope and provision of home PN
and EN services, which shall include, but not be
limited to the following:
2.2.1. The qualifications, roles, and responsi-
bilities of the referring physician, home
care provider, and nutrition support
practitioner(s).
2.2.2. Ongoing competency assessment pro-
gram for staff members.
2.2.3. Individuals authorized to prescribe
home PN and EN therapies.
2.2.4. Criteria for patient eligibility and selec-
tion, including medical suitability,
rehabilitative potential, home environ-
ment evaluation, social and economic
constraints, educational abilities, and
psychosocial factors.
2.2.5. A process for referral to a home care
provider for provision of parenteral or
enteral formulations, equipment, sup-
plies, and nursing care.
2.2.6. Education, training, and evaluation of
patient/caregiver competency.
2.2.7. A process for patient monitoring (eg,
frequency of follow-up, nutrition assess-
ment, laboratory studies, response to
nutrition therapy, and physical exami-
nation).
2.2.8. A process for referral to consultative
medical services, psychologists, social
workers, community resources, and
patient support groups, as appropriate.
2.2.9. Reimbursement processes for payment
of services, equipment, and supplies.
2.2.10. Preparation, storage of, and techniques
for administering PN or EN therapy in
the home.
2.2.11. Equipment and maintenance tracking
system.
2.2.12. Disposal of medical equipment and sup-
plies.
2.2.13. Prevention, management, and timely
response to complications in the home.
2.2.14. Emergency preparedness plan for the
home care provider, and for patients and
caregivers.
2.2.15. A process for timely communication and
collaboration among the referring physi-
cian, home care provider, nutrition sup-
port practitioner(s), patient, caregiver,
and other healthcare professionals
involved.
2.2.16. Discharge-from-service criteria for termi-
nation of services.
Standard 3. Access to Care
The patient/caregiver and all healthcare profes-
sionals involved in the care of the patient shall have
access to a home care provider that provides 24-hour
on-call services.
Standard 4. Medical Record
The home care provider shall initiate and main-
tain a medical record for every patient receiving
home PN or EN.
4.1. Confidentiality, sensitivity, and integrity of
data and information will be maintained in
compliance with the Health Insurance Portabil-
ity and Accountability Act.
4.1.1. Names and contact information of care-
givers who will assist in care of the
patient should be documented.
4.2. Medical records shall include, but not be lim-
ited to, documentation of the following:
4.2.1. Consent for care.
4.2.2. A treatment plan signed by the physi-
cian including prescriptions for PN or
EN therapies, medications, and orders
for activity level, access-site care, and
oral diet.
4.2.3. Contact information for the physician
or other nutrition support practitioners
shall be documented.
4.2.4. Functional status of the patient, per-
mitted activities, psychosocial needs,
suitability of home environment for
nutrition therapy.
4.2.5. All pertinent patient diagnoses, progno-
sis, and short-term and long-term treat-
ment objectives, and estimated dura-
tion of therapy.
4.2.6. Results of nutrition assessment and
findings on physical examination.
4.2.7. Education and training of patient
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and/or caregivers, including compe-
tency evaluation.
4.2.8. A current medication profile, including
prescription and nonprescription drugs,
vitamin/mineral supplements, oral
nutrition or herbal supplements, home
remedies, known drug allergies or sen-
sitivities, and history of tobacco use,
alcohol, and illicit drug use.
4.2.9. Signed and dated progress notes for
each contact between the home care
provider and the patient, referring phy-
sician or nutrition support practitio-
ner(s). Progress notes shall include
significant changes to therapy or com-
plications including the goals of ther-
apy, and shall report response to nutri-
tion therapy including but not limited
to results of serial monitoring, revisions
in the NCP, and patient compliance
with procedures and techniques.
4.2.10. Documentation at termination of nutri-
tion therapy should include but not be
limited to the following: reason for ter-
minating treatment, attainment of care
plan goals, complications, patient out-
come, and follow-up.
Standard 5. Performance Improvement
Nutrition support is a high-risk, problem-prone
treatment and shall be addressed in the home care
provider’s performance improvement and outcome
measurement activities.
5.1. Data to be collected shall include but not be
limited to mortality, hospital readmission, com-
plications, customer satisfaction, and problem-
reporting and resolution.
5.2. Outcomes shall be assessed in relation to inter-
nal or national benchmarks.
5.3. Sentinel events (rare but serious adverse out-
comes) related to treatment shall be appropri-
ately assessed and reported to appropriate reg-
ulatory agencies.
CHAPTER II: Nutrition Care Process
Standard 6. Nutrition Screening
Criteria shall be established for identification of
patients who are nutritionally-at-risk by an initial
screening mechanism.6–8
6.1. All patients admitted to the home care provider
shall undergo nutrition screening using subjec-
tive and/or objective criteria within 72 hours of
acceptance or on the initial home visit.9
6.2. The policy, procedure, and content of the nutri-
tion screen shall be formalized and docu-
mented.
6.3. The result of the nutrition screen shall be
documented.
6.4. Patients identified on initial screen as nutri-
tionally-at-risk shall be referred to the physi-
cian for further orders regarding nutrition
assessment and intervention.
6.5. Patients identified as not nutritionally-at-risk
shall be rescreened at regularly specified inter-
vals or when their clinical or nutrition status
changes.
Standard 7. Nutrition Assessment
All patients identified as nutritionally-at-risk by
the patient screening mechanism or requiring home
PN or EN shall have a nutrition assessment. The
results of the nutrition assessment and recommen-
dations should be shared with all patient care pro-
viders.
7.1. The nutrition assessment shall be performed
by, or under the supervision of, a registered
dietitian or healthcare professional with train-
ing and expertise in PN and EN within a time
frame specified by organizational policy.
7.2. Subjective and objective assessment of the
patient’s current nutrition status and require-
ments shall occur.10
7.2.1. The subjective assessment of nutrition
status should include a nutritionally
focused history. Elements that should be
documented as part of the subjective
assessment include the following: recent
changes in dietary intake (quantitative
and qualitative); mastication, swallow-
ing, gastrointestinal and elimination
symptoms (including stomatitis, nausea,
vomiting, diarrhea, constipation, and
anorexia); functional and anatomic sta-
tus of gastrointestinal tract, current sta-
tus and recent changes in functional
capacities (eg, ambulation, employment,
recreation, endurance, mental status);
psychosocial factors (eg, social support;
eating disorders; language barriers; fam-
ily dynamics; personal, ethnic, cultural,
or religious dietary prescriptions; sub-
stance abuse; psychiatric disorders);
socioeconomic factors (eg, personal finan-
cial situation); patient preferences and
directives with regard to intensity and
invasiveness of care; emotional response
to current illness; admitting diagnosis;
concurrent medical and surgical prob-
lems that may affect nutrition require-
ments; and nutrition support options,
including medications, allergies (food,
drug, or latex), and home remedies.
7.2.2. The objective assessment of nutrition
status should include data obtained from
the physical examination, anthropomet-
ric measurements, and laboratory data.
Elements of the physical examination
relevant to nutrition status should
include loss of subcutaneous fat, muscle
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wasting, presence of edema, ascites,
mucocutaneous lesions, hair and skin
changes, presence of wounds, and
patient specific indices as determined
from the subjective portion of the nutri-
tion assessment.
Anthropometric data that shall be doc-
umented include height, length, head cir-
cumference (if applicable), altered height
and weight relationship, current body
weight, ideal body weight, usual body
weight; recent change in weight (quanti-
fied), and body mass index.
Laboratory data9 that should be
reviewed and documented may include
complete blood count with differential;
serum electrolytes (including calcium,
phosphorous, and magnesium), blood
urea nitrogen, and creatinine; glucose;
albumin; aspartate aminotransferase;
alkaline phosphatase; total bilirubin;
prothrombin time; international normal-
ized ratio; and triglycerides.
7.3. If home PN or EN is indicated, the patient’s
home environment, medical suitability, rehabil-
itative potential, educational level or learning
ability, and reimbursement sources shall be
assessed by the physician, case manager,
and/or other designated healthcare profession-
als to determine the availability of appropriate
resources prior to initiation.
7.3.1. The patient’s home shall be determined
appropriate for the administration of
home PN or EN support; eg, the patient
should have a clean environment, sani-
tary water supply, electricity, refrigera-
tion, adequate storage space for supplies,
and access to a telephone.
7.3.2. The patient/caregiver shall be willing
and able to perform home PN and EN
therapy and associated procedures.
7.3.3. The patient/caregiver shall be able to
troubleshoot minor problems or call for
assistance when complications occur.
7.3.4. The patient/caregiver shall be informed
and knowledgeable about the rationale,
therapeutic goals and options, risks, ben-
efits, and responsibilities (financial and
otherwise) of home PN and EN and agree
to participate.
7.4. Initiation of PN in the home setting shall only
be considered in patients who are clinically
stable, have an appropriate indication for PN,
are able to be evaluated in the home, and are
capable of being educated in the safe adminis-
tration of the therapy. Initiating therapy at
home shall be considered only when assessment
confirms that the benefits greatly outweigh the
risks.
7.4.1. Review of patient’s medical and social
history, age, laboratory data, and indica-
tion for PN shall occur.
7.4.2. Laboratory data shall be obtained within
48 hours prior to initiation of home PN.9
More frequent assessment of laboratory
data may be required to ensure efficacy
and prevent complications of nutrition
support when initiated in the home. Lab-
oratory data may need to be modified for
pediatric patients.
7.4.3. High-risk patients who may not be can-
didates for the initiation of PN in the
home setting include patients at risk for
the refeeding syndrome; infants; IV drug
abusers; and patients with diabetes, fluid
and electrolyte/acid-base disorders, and
major organ dysfunction. Patients with
these conditions may need more frequent
monitoring and clinical assessment than
can be managed at home.
7.4.4. Once therapy is initiated, the patient/
caregiver must be able to: recognize vas-
cular access device (VAD) complications,
including signs and symptoms of cathe-
ter-related infection; recognize signs and
symptoms of fluid imbalance; perform
fingerstick glucose or urine testing for
glycosuria; recognize signs and symp-
toms of hyperglycemia or hypoglycemia;
and troubleshoot pump malfunction or
problems.
7.5. The results of the nutrition assessment shall be
summarized and documented.
7.5.1. A classification system for nutrition risk
according to the findings of the subjective
and objective nutrition assessments
shall be used.
7.5.2. Patient’s nutrition requirements shall be
summarized according to the findings of
the subjective and objective nutrition as-
sessments. The summary should include
appropriate route of administration, fluid,
protein and calorie requirements. The
summary should also include electrolyte
and micronutrient requirements.
7.6. Patients who are not considered candidates for
home PN or EN shall be provided with alterna-
tive choices/settings for receiving nutrition sup-
port.
CHAPTER III: Development of NCP
Standard 8. Interdisciplinary Approach
The NCP shall be developed with an interdiscipli-
nary approach involving the patient, the patient’s
referring physician, home care provider, and other
healthcare professionals involved in the care of the
patient as appropriate.
582 Vol. 20, No. 5KOVACEVICH ET AL
Standard 9. Objectives
The objective(s) of nutrition care shall be deter-
mined and documented. This should include imme-
diate and long-term goals of nutrition therapy,
anticipated duration of therapy, and patient educa-
tion.
Standard 10. Goals and Expectations
The NCP shall address patient and family care-
giver education about nutrition support therapy and
involvement in decisions regarding goals of treat-
ment.
10.1. The NCP shall include nutrition goals; route
for administration; prescribed nutrients; infu-
sion schedule; drug-nutrient interactions; spe-
cialized techniques of preparation and admin-
istration in the home setting; care of access
device, equipment, solutions, and formulas;
monitoring frequency; and a plan to implement
if problems related to infusion access devices,
equipment, or patient symptoms develop.
CHAPTER IV: Implementation and Education
Standard 11. Ordering Process
Implementation should commence after assess-
ment and development of an NCP.
11.1. Implementation of an NCP shall have a
defined ordering process.
11.2. Verbal prescriptions/orders for PN or EN ther-
apy shall be accepted only by personnel desig-
nated by the home care provider and authen-
ticated by the prescribing/ordering practitio-
ner within a defined time period or as required
under applicable law and/or regulations. All
verbal prescriptions or orders should be read
back to the prescribing/ordering practitioner.
11.3. Prescriptions/orders for PN or EN therapy
shall be maintained in the patient’s medical
record or received as required by law and
regulation before any therapy is administered.
Standard 12. Nutrition Support Access
The route selected to provide nutrition support
shall be appropriate to the patient’s medical prob-
lems, safety, efficacy, and patient preference.
12.1. When functional, the gastrointestinal tract is
the preferred route for nutrition support and
should be used to administer nutrition sup-
port.
12.2. PN should be provided only when the gastro-
intestinal tract is nonfunctional, cannot be
accessed, or when oral nutrition or EN would
exacerbate gastrointestinal tract dysfunction.1
12.3. Peripheral PN may be given through a periph-
eral-midline VAD and may be considered to
provide nutrition support until central access is
obtained.
12.4. Access shall be established by a healthcare pro-
fessional who is skilled and competent with the
insertion of the device in accordance with state
law and regulation.
12.5. Confirmation of VAD tip or enteral tube place-
ment is obtained and documented in the
patient’s medical record prior to administration
of therapy.
12.5.1. Central venous access shall be used for
administration of central PN. The cath-
eter tip should be positioned in the supe-
rior vena cava or adjacent to the right
atrium.1,11
12.6. Standard techniques and protocols shall be
established for the proper care and management
of the vascular and enteral access.11,12
Standard 13. PN Formulation Selection and
Preparation
PN formulations shall be prepared as prescribed,
appropriate for the patient’s disease process and
compatible with route of access.
13.1. PN formulations shall be appropriate for the
route of access.
13.2. PN formulations shall be adjusted as appro-
priate in patients with organ dysfunction.
13.3. PN formulations should be adjusted when
significant amounts of nutrients are provided
through means other than PN (eg, oral intake,
IV fluids, medications using a lipid-based
vehicle, peritoneal dialysis).
13.4. PN formulations shall be prepared using pol-
icies and procedures governing aseptic tech-
nique, manufacturing, compatibility, and sta-
bility.13,14
13.5. Automated compounding devices are recom-
mended for the compounding of PN formula-
tions. Personnel using automated compound-
ing devices shall be trained and demonstrate
competency. Training should include educa-
tion on operation, aseptic technique, appropri-
ate sequencing of additives, periodic calibra-
tion, troubleshooting, and maintenance of the
device. Procedures shall be developed and fol-
lowed to assure the quality of the preparation
process to minimize the risk of contamination,
especially by microorganisms.
13.5.1. PN formulations compounded by an
automated compounding device shall
be checked against the programmed
admixture and weight of components.
13.5.2. The operator shall continuously moni-
tor the automated compounding device
during the preparation process to
assure proper operation.
13.5.3. Demonstration of competency to safely
operate the automated compounding
device shall be assessed annually.
13.6. PN formulations shall be compounded under
sterile conditions and shall comply with
national standards.14,15
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13.6.1. Aseptic technique shall be taught, used,
and evaluated on a periodic basis.
13.6.2. PN admixtures shall be prepared in a
class 100 laminar airflow hood using
aseptic technique14,15 and under the
direction of a pharmacist.16
13.6.3. The compounding room should be a
controlled room with limited access to
decrease the potential for contamina-
tion of sterile compounded products.
13.7. The final PN formulation shall be checked
visually to assure appropriate volume,
absence of particulate matter or phase sepa-
ration in the IV fat emulsion (IVFE).13
13.8. All PN formulations shall be prepared in com-
patible containers and shall be administered
through a filter. A 0.22-m filter shall be used
for 2-in-1 formulations. A 1.2-m filter shall
be used for total nutrient admixtures (TNAs).
Alternatively, a 1.2-m filter may be used for
all PN formulations.13
13.9. Methods should be taken to limit the amount
of aluminum contamination in PN formula-
tions.17,18
Standard 14. Packaging and Labeling PN
Formulations
PN formulations shall be visually inspected dur-
ing preparation, prior to hanging, and during
administration to identify potential incompatibili-
ties of the formulation (ie, calcium/phosphate pre-
cipitation). PN formulations shall be labeled appro-
priately, including administration date and time
and beyond-use date, in compliance with the
A.S.P.E.N. Safe Practices Task Force for Parenteral
Nutrition13,14 and any applicable state regulations.
Labeling shall also include any special patient
instructions (ie, additives, activation of dual cham-
ber bags, and cycling schedule).
Standard 15. Additives to PN Formulations
Additives to PN formulations shall be appropriate
and compatible with all ingredients.
15.1. All patients receiving PN should receive
daily parenteral multivitamins in quantities
established by the US Food and Drug Admin-
istration (FDA) Center for Drug Evaluation
and Research.19,20
15.2. All additions to a PN formulation such as
multivitamins shall be made by the patient or
caregiver in a designated clean area as
instructed by the home care provider. Paren-
teral multivitamins should be added immedi-
ately before starting the PN infusion.
15.3. If parenteral iron is clinically indicated, it may
be administered as various forms of IV iron.
Only iron dextran can be added to a bag that
does not contain IVFE. An iron dextran test
dose is required before the initial infusion. The
other choices for iron replacement require a
separate infusion.
15.4. Any additions to a PN formulation by the
patient or caregiver shall be approved by the
home care provider.
15.5. The addition of concentrated electrolytes to PN
formulations in the home setting should be
avoided.21
15.6. Addition of electrolytes and medications to a
PN formulation after administration has begun
shall be avoided.
15.7. Healthcare professionals responsible for the
preparation and delivery of PN formulations
shall use methods for detection or prevention of
formulation incompatibilities.
15.8. All patients receiving PN should receive daily
parenteral trace elements. Dosing may need to
be adjusted for severe renal and hepatic dys-
function, excessive losses, or in patients receiv-
ing long-term PN.1
15.9. The addition of calcium and phosphate to PN
formulations should comply with guidelines13
in the literature and manufacturer’s guidelines
for automated compounding.
15.10. Use of calcium chloride shall be avoided due to
greater risk of electrolyte and nutrient incom-
patibility. Calcium gluconate salt is the pre-
ferred choice when compounding PN formula-
tions.
15.10.1. Calcium and phosphate salts should
not be added in close sequence or con-
secutively to the PN formulation.
15.10.2. Phosphate should be added prior to
the addition of calcium during the
compounding process.
15.10.3. Some amino acid formulations contain
phosphorus and must be accounted for
in the calculation of calcium/phospho-
rus solubility.
15.11. Any additive lacking compatibility and stability
data in standard reference sources should not
be added to PN formulations.
Standard 16. EN Formulation Selection and
Preparation
EN formulations shall be prepared as prescribed,
appropriate for the patient’s disease process and
compatible with route of access.
16.1. EN formulations shall be prepared to prevent
contamination. Commercially available EN
formulations shall be used whenever possible.
16.2. EN formulations shall be prepared by the
patient/caregiver who has been trained in
accordance with policies and procedures and
manufacturer’s instructions.
16.3. EN formulation preparation equipment shall
be routinely sanitized.
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Standard 17. EN Formulation Packaging and Labeling
EN formulations shall be appropriately packaged
and labeled.
17.1. EN formulations shall be packaged in contain-
ers that can assure cleanliness during prepa-
ration, storage, and administration.
17.2. EN formulations shall be packaged in contain-
ers that assure cleanliness and accuracy of
administration.
Standard 18. Additives to EN Formulations
Additives to EN formulations shall be safe, stable,
and compatible with all ingredients.
18.1. Healthcare professionals responsible for the
preparation and administration of EN formu-
lations shall have resources available to docu-
ment compatibility and stability of any addi-
tives.
18.1.1. Compatible medications should be
administered individually in a manner
to avoid tube occlusion and to attain
desired therapeutic response. The
tube should be flushed after adminis-
tration of any medication.
18.1.2. Modular nutrition components can
be added to EN formulas to increase
calories, protein, or fiber as deemed
appropriate by the patient’s health-
care provider. They should be diluted
as necessary to prevent occlusion of
feeding apparatus.
18.2. Colorants (food coloring or methylene blue dye)
should not be added to EN formulations.22,23
Standard 19. Storage and Administration of PN and
EN Formulations
PN and EN formulations shall be stored and
administered accurately in accordance with the pre-
scribed therapeutic plan and consistent with the
patient’s tolerance.
19.1. PN formulations should be stored under
refrigerated conditions (35.6°F–46.4°F) and
warmed to room temperature prior to infu-
sion.13,14
19.2. Temperature control during transport of ster-
ile products for home use shall be maintained
to ensure the stability and integrity of the
products in accordance with manufacturer’s
recommendations or currently accepted stan-
dards.
19.3. Unopened and partially used commercially
available EN products should be stored at
temperatures as recommended by the manu-
facturer.
19.4. The use of home prepared or blenderized EN
formulations requires additional attention to
nutrient content and safe food handling and
storage practices. They should be stored under
refrigeration and discarded after 48 hours.24
19.5. Protocols shall be written regarding tech-
niques used to administer EN and PN formu-
lations.
19.5.1. Protocols shall be written to prevent
enteral feeding tube or VAD occlusion.
19.5.2. A protocol shall be written to prevent
infection due to the feeding formula-
tion and the equipment used in its
administration.
19.5.3. A protocol shall be written regarding
the appropriate hang time for PN and
EN formulations.25,26
19.5.3.1. Once started, the infusion of
a PN formulation shall be
completed within 24 hours or
the remaining formulation
shall be discarded.11
19.5.3.2. Infusion of IVFE as a sepa-
rate infusion should be com-
pleted within 12 hours or dis-
carded.25
19.5.4. A protocol should be written to prevent
the inadvertent administration of an
EN formulation through a VAD.27
19.6. The nutrient infusion method and infusion
control device selected for administration of
PN or EN shall be suitable for home use.
19.7. Selection of the nutrient infusion method or
infusion control device should be based on
clinical need, safety, accuracy of delivery, and
cost-effectiveness.
19.8. Consideration should be given to patient pref-
erence, volume to be infused, type of regimen
(cyclic, continuous, or intermittent), activity
level of the patient, reimbursement issues,
and ability/education level.
19.9. PN formulations shall be infused using a
pump.
Standard 20. Patient/Caregiver Education on Home
PN Administration
The patient/caregiver shall receive education by
qualified members of the healthcare team and dem-
onstrate competence in the preparation and admin-
istration of home PN. The education and training
are specific to the patient’s assessed needs, abilities,
and readiness, as appropriate to the care and service
provided. This competency and compliance is period-
ically assessed and documented.
20.1. The patient receiving home PN or caregiver
should be instructed on the safe and effective
use of PN formulations in accordance with
legal requirements, including the following:
20.1.1. Name and telephone numbers of
resources available 24-hours-a-day to
troubleshoot and answer questions.
20.1.2. The name, composition, intended
use, and expected outcome of the for-
mulation.
20.1.3. Medication information and adminis-
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tration, including dosage, route, fre-
quency, and the potential for adverse
effects and drug interactions.
20.1.4. Inspection of home PN containers to
assure that the PN bag is intact and
there are no leaks.
20.1.5. Inspection of the contents before and
after any additives are added to
assure there are no precipitates,
changes in color, or any disruption/
destabilization in the TNA.
20.1.6. Instruction on the safe addition of
any additives, including mixing and
inspection of the final PN formula-
tions. Importance of not adding any
medications not prescribed to the PN
to prevent nutrient-drug interactions.
20.1.7. The route of administration and dura-
tion of nutrition therapy.
20.1.8. Proper VAD and site care.
20.1.9. Inspection of label prior to administra-
tion to ensure the prescribed PN formu-
lation is given to the appropriate
patient.
20.1.10. Connecting and disconnecting the IV
tubing to the VAD.
20.1.11. Pre- and/or postinfusion flushing to
maintain VAD patency and prevent
drug-nutrient incompatibility.
20.1.12. Infection control and prevention,
including aseptic technique required
for any admixture procedures and
administration via access device,
appropriate handwashing techniques,
and standard precautions.
20.1.13. Verification of proper pump program-
ming each time a new volume of PN is
ordered.
20.1.14. Compatibility and stability of PN and
coadministered solutions under refrig-
eration or at room temperature.
20.1.15. Techniques for self-monitoring and
identification of potential complications
of therapy.
20.1.16. Proper storage of the PN bag and iden-
tification of the “do not use after” or
“beyond use” date on the label of the PN
bag.
20.1.17. Use and storage of infusion pump and
supplies, including safety, cleaning,
disinfecting, emergency backup, and
troubleshooting.
20.1.18. Proper disposal of used containers, tub-
ing, needles, and unused or outdated
PN and/or medications.
20.1.19. Action to be taken in the event of late or
missed administration of PN.
20.1.20. Process to order additional PN, patient
additives, or supplies.
20.1.21. Basic home safety (fire, electrical, envi-
ronment, mobility, bathroom).
20.1.22. Information on emergency prepared-
ness to assist patients and caregivers if
an emergency should interrupt service.
Standard 21. Patient/Caregiver Education on Home
EN Administration
The patient/caregiver shall receive education by
qualified members of the healthcare team and dem-
onstrate competence in the preparation and admin-
istration of home EN. The education and training
are specific to the patient’s assessed needs, abilities,
and readiness, as appropriate to the care and service
provided. This competency and compliance is peri-
odically assessed and documented.
The patient receiving home PN or caregiver
should be instructed on the safe and effective use of
PN formulations in accordance with legal require-
ments, including the following:
21.1. The name, composition, intended use, and
expected outcome from the formulation.
21.2. Medication information and administration,
including dosage, route, frequency, and the
potential for adverse effects and drug inter-
actions.
21.3. Timing, method of administration, and feed-
ing schedule.
21.4. The route of administration and duration of
nutrition therapy.
21.5. Care of the enteral access device.
21.6. Product hang time and stability at room
temperature.
21.7. Inspection of enteral products for contents
and expiration date.
21.8. Clean technique for preparation of EN,
administration, and reuse of supplies and
equipment.
21.9. Techniques for self-monitoring of therapy
and identification of potential complications.
21.10. Proper storage of ready-to-use formula and
feeding formulations that require mixing.
21.11. Use and storage of enteral feeding equipment
and supplies (including safety, cleaning, dis-
infecting, emergency backup, and trouble-
shooting).
21.12. Proper disposal of used containers, tubing,
and unused and/or expired feeding formula-
tions or medications.
21.13. Action to be taken in the event of late or
missed administration of EN.
21.14. Process to order additional feeding formula-
tion and supplies.
21.15. Infection prevention and control, ie, standard
precautions.
21.16. Basic home safety (fire, electrical, environ-
ment, mobility, bathroom).
21.17. Information on emergency preparedness to
assist patients and caregivers if an emer-
gency should interrupt service.
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CHAPTER V: Patient Monitoring
Standard 22. Parameters and Frequency
Patient monitoring shall be designed to deter-
mine the effectiveness and appropriateness of nutri-
tion support. The process of patient monitoring must
assure that the nutrition goals are achieved. The
monitoring process is also intended to reduce the
risk of complications due to nutrition support. Each
patient’s nutrition status is monitored and docu-
mented on a regular basis.
22.1. The referring physician, home care provider,
and nutrition support practitioner(s) should
monitor the clinical status and response to
nutrition therapy. This shall include but not
be limited to the following:
● Observation for signs and symptoms of
intolerance to therapy
● Evaluation of weight changes and/or growth
rates as appropriate
● Evaluation of hydration status
● Review of systems and/or physical examina-
tion
● Periodic review of biochemical and/or other
pertinent laboratory data
● Assessment for clinical signs of nutrient
deficiencies or excesses
● Assessment of other disease states or condi-
tions that may affect the nutrition therapy
● Review for evidence of an interaction
between the nutrition therapy and medica-
tions or other disease states
● Evaluation of functional status and perfor-
mance
● Inspection of access device and site
● Patient compliance with techniques and pro-
cedures of the nutrition therapy and inven-
tory of formulations
22.2. Review the appropriateness of the nutrition
therapy, therapeutic regimen, and route of
administration. This shall include but not be
limited to:
● Assessment of the impact of the current
medication regimen on the nutrition therapy
● Assessment of the need for continued nutri-
tion support
● Periodic review of the psychosocial status
(patient and/or caregiver) and home environ-
ment of the patient
● Monitoring of fluid, nutrient, and oral intake
● Monitoring of urine, stool, and other gastroin-
testinal losses or output
● Review appropriateness of the route of admin-
istration
22.3. PN or EN should be modified or discontinued
when indicated by the severity or magnitude of
associated complications.
22.3.1. Protocols shall be developed to identify
mechanical, metabolic, and infectious
complications necessitating interruption
of nutrition support.
22.4. Communicate and document the results of the
patient monitoring process to the physician and
other healthcare professionals involved in the
patient’s care.
CHAPTER VI: Review and Revision of NCP
Standard 23. Evaluation of NCP
The NCP is reviewed and revised as necessary.
23.1. The home PN and EN treatment and care plan
shall be reviewed, evaluated, and updated by
the referring physician, home care provider,
and other healthcare professionals to deter-
mine overall appropriateness, effectiveness,
and safety of the treatment.
23.2. Patients shall be reassessed to determine the
effectiveness of care in meeting therapeutic
goals. Revision of the NCP may be required
when changes occur in the patient’s clinical
condition, response to therapy, environment
or psychosocial status, drugs/therapy, or when
nutrition goals are not met.
23.3. All revisions of the NCP shall be documented
in the patient’s medical record.
23.4. The route of nutrition support shall be period-
ically reassessed for adequacy, appropriate-
ness, efficacy, and safety.
CHAPTER VII: Transition and Termination of
Therapy
Standard 24. Transition Feeding
24.1. During the transition from PN to EN, or PN to
oral intake, or EN to oral intake, the patient
shall demonstrate tolerance to the final nutri-
tion support regimen.
24.2. Adequate nutrient from oral intake should be
demonstrated prior to discontinuing PN and
or EN.
24.2.1. Oral nutrient intake should be docu-
mented.
24.2.2. When appropriate, PN or EN should
be gradually decreased as oral intake
increases so that overall adequate
nutrient intake is sustained.
24.2.3. If oral nutrient intake is suboptimal,
PN or EN should not be discontinued.
24.3. If follow-up nutrition care is indicated, written
and/or verbal information is given to the
patient/caregiver.
Standard 25. Termination of Therapy
25.1. PN or EN should be terminated when the
patient no longer benefits from therapy or the
burden outweighs the benefit.1,28
25.2. Patients and/or their designated representa-
tive, according to patient’s competence, shall
be involved in decisions regarding the with-
drawal of nutrition support.
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25.3. Protocols shall exist to permit the discontinu-
ation of PN and EN in accordance with patient
advance directives, medical ethics, local prac-
tice standards, and current local, state, and
federal law.
CHAPTER VIII: Definitions
The following terms that are used in these stan-
dards have been defined previously in A.S.P.E.N.
Guidelines and Standards or by other organizations
as referenced.
Automated Compounding Device. A device used in
the preparation of PN. It automates the transfer of
dextrose, amino acids, fat emulsion, sterile water, as
well as small-volume injectables, such as electro-
lytes and minerals to the final PN container. The
device is driven by computer software.
Beyond-Use Date. The date established by health-
care professionals from the published literature or
manufacturer-specific recommendations beyond
which the pharmacy-prepared product should not be
used.
Care Plan. Plan of professional clinical activities
developed to implement the treatment plan.
Clinical Guidelines. Systematically developed
statements to assist practitioner and patient deci-
sions about appropriate healthcare for specific clin-
ical circumstances.29
Compatibility. The ability to combine 2 or more
chemical products such that the physical integrity of
the products is not altered. Incompatibility refers to
concentration-dependent precipitation or acid-base
reactions that result in physical alteration of the
products when combined together.
Drug-Drug Interaction. An event that occurs when
a drug’s activity, availability, or effect is altered by
another drug.
Drug-Nutrient Interaction. An event that occurs
when nutrient availability is altered by a medica-
tion, or when a drug effect is altered, or an adverse
reaction caused by the intake of nutrients.
Enteral Access Devices. Tubes placed directly into
the gastrointestinal tract for the delivery of nutri-
ents or drugs.
Enteral Nutrition (EN). Nutrition provided
through the gastrointestinal tract via a tube, cathe-
ter, or soma that delivers nutrients distal to the oral
cavity.
Oral. EN taken by mouth.
Tube. EN provided through a tube, catheter, or
stoma that delivers nutrients distal to the oral
cavity.
Expiration Date. The date established from sci-
entific studies to meet the FDA regulatory
requirements for commercially manufactured
drug products beyond which the product should not
be used.
Formulation. A ready-to-administer mixture of
nutrients.
Hang Time. The period of time beginning with the
flow of a fluid through an administration set and
catheter or feeding tube and ending with the com-
pletion of the infusion.
Indicators. Prospectively determined measures
used as normative standards within a performance
improvement process.
Intravenous Fat Emulsant (IVFE). An IV oil-in-
water emulsion of oil(s), egg phosphatides, and glyc-
erin. The term should be used in preference to lipids.
Malnutrition. Any disorder of nutrition status,
including disorders resulting from a deficiency of
nutrient intake, impaired nutrient metabolism, or
overnutrition.
Nutrition Assessment. A comprehensive approach
to defining nutrition status that uses medical, nutri-
tion, and medication histories; physical examina-
tion; anthropometric measurements; and laboratory
data. A formal nutrition assessment should provide
all of the information necessary to develop an appro-
priate NCP. Because of the inextricable relationship
between malnutrition and severity of illness and the
fact that tools of nutrition assessment reflect both
nutrition status and severity of underlying disease,
an assessed state of malnutrition or presence of
specific indicators of malnutrition in fact refers to
the consequences of a combination of an underlying
illness and associated nutrition changes and defi-
cits.
Nutritionally-at-Risk Adults. Adults are consid-
ered at nutrition risk if they have any of the follow-
ing:
● Actual or potential for developing malnutri-
tion (involuntary loss or gain of 10% of
usual body weight within 6 months or 5% of
usual body weight in 1 month, a weight of
20% over or under ideal body weight), presence
of chronic disease, or increased metabolic
requirements.
● Altered diets or diet schedules (receiving total
PN or EN, recent surgery, illness, or trauma).
● Inadequate nutrition intake, including not
receiving food or nutrition products (impaired
ability to ingest or absorb food adequately) for
7 days.
Nutritionally-at-Risk Children. Children should
be considered at nutrition risk if they have:
● A weight/length or weight for height less than
the 10th percentile or greater than the 90th
percentile.
● Increased metabolic requirement.
● Impaired ability to ingest or tolerate oral feed-
ings.
● Documented inadequate provision or tolerance
of nutrients.
● Inadequate weight gain or a significant de-
crease in an individual’s usual growth percen-
tile.
Nutritionally-at-Risk Neonates. Neonates should
be considered at nutrition risk if they have:
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● Very low birth weight (1500 g) or low birth
weight (2500 g), even in the absence of gas-
trointestinal, pulmonary, or cardiac disorders.
● Birth weight 2 standard deviations below the
mean (approximately the 3rd percentile for ges-
tational age on fetal weight curves).
● Acute weight loss of 10% or more.
Nutrition Care. Interventions and counseling of
individuals on appropriate nutrition intake through
the integration of information from the nutrition
assessment.
Nutrition Care Plan (NCP). A formal statement of
the nutrition goals and interventions prescribed for
an individual using the data obtained from a nutri-
tion assessment. The plan, formulated by an inter-
disciplinary process, should include statements of
nutrition goals and monitoring parameters, the
most appropriate route of administration of special-
ized nutrition support (oral, enteral, and/or paren-
teral) method of nutrition access, anticipated dura-
tion of therapy, and training and counseling goals
and methods.
Nutrition Screening. A process to identify an indi-
vidual who is malnourished or who is at risk for
malnutrition to determine if a detailed nutrition
assessment is indicated.
Nutrition Support Service (or Team). A multidis-
ciplinary group of healthcare professionals, includ-
ing a physician, nurse, dietitian, and pharmacist
with expertise in nutrition, who manage the provi-
sion of SNS.
Nutrition Therapy. A component of medical treat-
ment that includes oral nutrition, EN, and PN.
Oral Nutrition. Nutrition taken by mouth.
Outcome. The measured result of the performance
of a system or process.
Parenteral Nutrition (PN). The administration of
nutrients intravenously.
Central. PN delivered into a large-diameter
vein, usually the superior vena cava.
Peripheral. PN delivered into a peripheral vein,
usually of the hand or forearm.
Pediatric. Patients  17 years old, including pre-
mature newborns, neonates, infants, toddlers, chil-
dren, and adolescents.
Specialized Nutrition Support (SNS). Provision of
nutrients orally, enterally, or parenterally with
therapeutic intent. This includes, but is not limited
to, provision of total EN or PN support to maintain
and/or restore optimal nutrition status and health.
Stability. The extent to which a product retains,
within specified limits and throughout its period of
storage and use (ie, its shelf life), the same proper-
ties and characteristics that it possessed at the time
of its manufacture.
Standard. Benchmark representing a range of
performance of competent care that should be pro-
vided to assure safe and efficacious nutrition care.
Total Nutrient Admixture (TNA). A PN formula-
tion containing IVFE as well as the other compo-
nents of PN (carbohydrate, amino acids, vitamins,
minerals, trace elements, water, and other addi-
tives) in a single container.
Treatment Plan. Orders established and signed by
a clinician with prescriptive rights for the care of the
patient (ie, the medical orders, including nutrients,
medications, activity orders, access site orders, etc).
Vascular Access Devices (VAD). A device inserted
into a vein that permits administration of intermit-
tent or continuous infusion of parenteral solutions
or medications.
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